Information on individual cases may provide a valuable first clue on presence of teratogenic risks after marketing of drugs. An important, and high qualitative source of these cases, may be Teratology Information Services (TIS), since detailed information exposures and risk factors can be retrieved when a TIS is contacted.
In this presentation the way of working, possibilities and pitfalls of the analysis of these type of cases will be discussed, taken into account the experiences in the field of detection of generic adverse drug reactions by (national) pharmacovigilance centres in the postmarketing phase.